Search

Your search keyword '"Bjorkholm, M"' showing total 37 results
Start Over Author "Bjorkholm, M" Database OAIster
37 results on '"Bjorkholm, M"'

1. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden

Author

Hultcrantz, M., Landtblom, A. Ravn, Andreasson, B., Samuelsson, Jan, Dickman, P. W., Kristinsson, S. Y., Bjorkholm, M., Andersson, T. M-L, Hultcrantz, M., Landtblom, A. Ravn, Andreasson, B., Samuelsson, Jan, Dickman, P. W., Kristinsson, S. Y., Bjorkholm, M., and Andersson, T. M-L

Abstract

Background The reported incidence of Philadelphia-negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers. Objective We therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers. Methods Patients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age-standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated. Results A total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000-2014. The age-standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34-4.56)/100 000 person-years. The age-standardized incidence for polycythemia vera was 1.48 (1.42-1.54), for essential thrombocythemia 1.60 (1.53-1.66) and for primary myelofibrosis 0.52 (0.48-0.56)/100 000 person-years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population. Conclusion The reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population-based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers., Funding Agencies|Karolinska InstitutetKarolinska Institutet; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748, P30 CA008748]; Stockholm County CouncilStockholm County Council; Swedish Research CouncilSwedish Research Council; Blodcancerfonden; Cancer Research Foundations of Radiumhemmet

Published
2020
Full Text
View/download PDF

2. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : a population-based study in Sweden

Author

Gunnarsson, N., Höglund, Martin, Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, Ulla, Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, N., Höglund, Martin, Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, Ulla, Wadenvik, H., Richter, J., and Sjalander, A.

Published
2017
Full Text
View/download PDF

3. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : a population-based study in Sweden

Author

Gunnarsson, Niklas, Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, Niklas, Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., and Sjalander, A.

Published
2017
Full Text
View/download PDF

4. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Author

Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., and Sjalander, A.

Abstract

n/a, Funding Agencies|Emil Andersson Research Fund; Nordic CML Study Group

Published
2017
Full Text
View/download PDF

5. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Author

Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., and Sjalander, A.

Abstract

n/a, Funding Agencies|Emil Andersson Research Fund; Nordic CML Study Group

Published
2017
Full Text
View/download PDF

6. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : a population-based study in Sweden

Author

Gunnarsson, Niklas, Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, Niklas, Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., and Sjalander, A.

Published
2017
Full Text
View/download PDF

7. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Author

Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., and Sjalander, A.

Abstract

n/a, Funding Agencies|Emil Andersson Research Fund; Nordic CML Study Group

Published
2017
Full Text
View/download PDF

8. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Author

Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., and Sjalander, A.

Abstract

n/a, Funding Agencies|Emil Andersson Research Fund; Nordic CML Study Group

Published
2017
Full Text
View/download PDF

9. No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Author

Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., Sjalander, A., Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, Arta, Lambe, M., Markevarn, B., Olsson-Stromberg, U., Wadenvik, H., Richter, J., and Sjalander, A.

Abstract

n/a, Funding Agencies|Emil Andersson Research Fund; Nordic CML Study Group

Published
2017
Full Text
View/download PDF

10. Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma

Author

University of Helsinki, Clinicum, Pauly, F., Fjorden, K., Leppa, S., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. Moller, Eriksson, M., Isinger-Ekstrand, A., Borrebaeck, C. A. K., Jerkeman, M., Wingren, C., University of Helsinki, Clinicum, Pauly, F., Fjorden, K., Leppa, S., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. Moller, Eriksson, M., Isinger-Ekstrand, A., Borrebaeck, C. A. K., Jerkeman, M., and Wingren, C.

Published
2016

11. MULTIPLE MYELOMA PATIENTS THAT DEVELOP SECOND PRIMARY MALIGNANCY HAVE A WORSE PROGNOSIS THAN MULTIPLE MYELOMA PATIENTS TREATED BEFORE THE INTRODUCTION OF NOVEL AGENTS : A POPULATION BASED-STUDY

Author

Jonsdottir, G., Lund, S. H., Landgren, O., Bjorkholm, M., Turesson, I., Wahlin, Anders, Blimark, C., Hultcrantz, M., Porwit, A., Kristinsson, S. Y., Jonsdottir, G., Lund, S. H., Landgren, O., Bjorkholm, M., Turesson, I., Wahlin, Anders, Blimark, C., Hultcrantz, M., Porwit, A., and Kristinsson, S. Y.

Published
2014

13. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients : results of a phase II Nordic Lymphoma Group study

Author

Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundström, Christer, Karjalainen-Lindsberg, M. -L, Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M., Eriksson, M., Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundström, Christer, Karjalainen-Lindsberg, M. -L, Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M., and Eriksson, M.

Abstract

Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years. Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months. Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov.identifier: NCT01502982.

Published
2013
Full Text
View/download PDF

14. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients : results of a phase II Nordic Lymphoma Group study

Author

Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M. -L, Erlanson, Martin, Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M., Eriksson, M., Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M. -L, Erlanson, Martin, Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M., and Eriksson, M.

Abstract

Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years. Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months. Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov.identifier: NCT01502982.

Published
2013
Full Text
View/download PDF

15. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study

Author

Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M. -L., Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, Harald, Jerkeman, Mats, Eriksson, Mikael, Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M. -L., Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, Harald, Jerkeman, Mats, and Eriksson, Mikael

Abstract

Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years. Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months. Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov.identifier: NCT01502982.

Published
2013

16. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms

Author

Bjorkholm, M., Derolf, A.R., Hultcrantz, M., Kristinsson, S.Y., Ekstrand, C., Goldin, L.R., Andreasson, B., Birgegard, G., Linder, O., Malm, Claes, Markevarn, B., Nilsson, L., Samuelsson, J., Granath, F., Landgren, O., Bjorkholm, M., Derolf, A.R., Hultcrantz, M., Kristinsson, S.Y., Ekstrand, C., Goldin, L.R., Andreasson, B., Birgegard, G., Linder, O., Malm, Claes, Markevarn, B., Nilsson, L., Samuelsson, J., Granath, F., and Landgren, O.

Abstract

Purpose: Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to develop acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs). Using population-based data from Sweden, we assessed the role of MPN treatment and subsequent AML/MDS risk with special focus on the leukemogenic potential of hydroxyurea (HU). Methods: On the basis of a nationwide MPN cohort (N = 11,039), we conducted a nested case-control study, including 162 patients (153 and nine with subsequent AML and MDS diagnosis, respectively) and 242 matched controls. We obtained clinical and MPN treatment data for all patients. Using logistic regression, we calculated odds ratios (ORs) as measures of AML/MDS risk. Results: Forty-one (25%) of 162 patients with MPNs with AML/MDS development were never exposed to alkylating agents, radioactive phosphorous (P32), or HU. Compared with patients with who were not exposed to HU, the ORs for 1 to 499 g, 500 to 999 g, more than 1,000 g of HU were 1.5 (95% CI, 0.6 to 2.4), 1.4 (95% CI, 0.6 to 3.4), and 1.3 (95% CI, 0.5 to 3.3), respectively, for AML/MDS development (not significant). Patients with MPNs who received P32 greater than 1,000 MBq and alkylators greater than 1 g had a 4.6-fold (95% CI, 2.1 to 9.8; P = .002) and 3.4-fold (95% CI, 1.1 to 10.6; P = .015) increased risk of AML/MDS, respectively. Patients receiving two or more cytoreductive treatments had a 2.9-fold (95% CI, 1.4 to 5.9) increased risk of transformation. Conclusion: The risk of AML/MDS development after MPN diagnosis was significantly associated with high exposures of P32 and alkylators but not with HU treatment. Twenty-five percent of patients with MPNs who developed AML/MDS were not exposed to cytotoxic therapy, supporting a major role for nontreatment-related factors. © 2011 by American Society of Clinical Oncology.

Published
2011
Full Text
View/download PDF

17. A phase II trial of pegylated interferon a-2b therapy for polycythemia vera and essential thrombocythemia : Feasibility, clinical and biologic effects, and impact on quality of life

Author

Samuelsson, J., Hasselbalch, H., Bruserud, O., Temerinac, S., Brandberg, Y., Merup, M., Linder, O., Bjorkholm, M., Pahl, H.L., Birgegard, G., Ghanima, W., Gram-Hansen, P., Johansson, P., Malm, C., Markevam, B., Mourits-Andersen, T., Nillson, L., Samuelsson, J., Hasselbalch, H., Bruserud, O., Temerinac, S., Brandberg, Y., Merup, M., Linder, O., Bjorkholm, M., Pahl, H.L., Birgegard, G., Ghanima, W., Gram-Hansen, P., Johansson, P., Malm, C., Markevam, B., Mourits-Andersen, T., and Nillson, L.

Abstract

BACKGROUND. Conventional interferon-a (IFN) is an effective treatment for patients with myeloproliferative disorders. However, many patients discontinue therapy because of side effects. METHODS. In this 24-month, Phase II feasibility study of pegylated interferon a-2b (PEG-IFN) treatment, a starting dose of 0.5 µg/kg per week was received by 21 patients with polycythemia vera (PV) and 21 patients with essential thrombocythemia (ET). The treatment objective, a complete platelet response (CR), was a platelet count <400 × 109/L in symptomatic patients and <600 in asymptomatic patients. Neutrophil polycythemia rubra vera-1 (PRV-1) messenger RNA expression was analyzed prior to and during therapy. Quality of life (QoL) was investi-gated by using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. RESULTS. At 6 months, 29 of 42 patients (69%) had achieved a CR after a median of 83 days. The CR rate was not related to diagnosis, gender, or previous therapy. Nineteen patients completed the planned 2-year treatment in CR. No thromboembolic or bleeding complications were observed. Phlebotomy requirements were reduced in the majority of patients with PV. Five of 14 patients (36%) who initially were positive for PRV-1 achieved normalized PRV-1 expression under PEG-IFN treatment. Side effects were the cause of therapy failure in 16 of 23 patients. However, only 8 of 19 patients reported any side effects at 2 years. The QLQ-C30 revealed clinically significant impairments in several aspects of QoL at 6 months, however, at 2 years, QoL measurements were not different from baseline. CONCLUSIONS. PEG-IFN effectively reduced platelet counts in 29 of 42 patients, but only 19 patients maintained a CR at 2 years. The reversal of PRV-1 positivity noted in a subset of patients suggested that PEG-IFN may have an effect on the malignant clone. PEG-IFN is a valuable therapeutic alternative for patients who tolerate its initial side effects. © 2006 American Ca

Published
2006
Full Text
View/download PDF

18. Granulocyte-macrophage colony-stimulating factor to increase efficacy ofmitoxantrone, etoposide and cytarabine in previously untreated elderlypatients with acute myeloid leukaemia: a Swedish multicentre randomizedtrial.

Author

Lofgren, C, Paul, C, Astrom, M, Hast, R, Hedenius, M, Lerner, R, Liliemark, J, Nilsson, I, Rodjer, S, Simonsson, B, Stockelberg, D, Tidefelt, U, Bjorkholm, M, Lofgren, C, Paul, C, Astrom, M, Hast, R, Hedenius, M, Lerner, R, Liliemark, J, Nilsson, I, Rodjer, S, Simonsson, B, Stockelberg, D, Tidefelt, U, and Bjorkholm, M

Published
2004

19. No benefit from adding GM-CSF to induction chemotherapy in transformingmyelodysplastic syndromes: better outcome in patients with lessproliferative disease.

Author

Hast, R, Hellstrom-Lindberg, E, Ohm, L, Bjorkholm, M, Celsing, F, Dahl, IM, Dybedal, I, Gahrton, G, Lindberg, G, Lerner, R, Linder, O, Lofvenberg, Eva, Nilsson-Ehle, H, Paul, C, Samuelsson, J, Tangen, JM, Tidefelt, U, Turesson, Ingela, Wahlin, A, Wallvik, J, Winquist, I, Oberg, G, Bernell, P, Hast, R, Hellstrom-Lindberg, E, Ohm, L, Bjorkholm, M, Celsing, F, Dahl, IM, Dybedal, I, Gahrton, G, Lindberg, G, Lerner, R, Linder, O, Lofvenberg, Eva, Nilsson-Ehle, H, Paul, C, Samuelsson, J, Tangen, JM, Tidefelt, U, Turesson, Ingela, Wahlin, A, Wallvik, J, Winquist, I, Oberg, G, and Bernell, P

Published
2003

21. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined withdaunorubicin and cytarabine in patients with relapsed and primaryrefractory acute myeloid leukemia.

Author

Gruber, A, Bjorkholm, M, Brinch, L, Evensen, S, Gustavsson, B, Hedenus, M, Juliusson, G, Lofvenberg, E, Nesthus, I, Simonsson, B, Sjo, M, Stenke, L, Tangen, JM, Tidefelt, U, Uden, AM, Paul, C, Liliemark, J, Gruber, A, Bjorkholm, M, Brinch, L, Evensen, S, Gustavsson, B, Hedenus, M, Juliusson, G, Lofvenberg, E, Nesthus, I, Simonsson, B, Sjo, M, Stenke, L, Tangen, JM, Tidefelt, U, Uden, AM, Paul, C, and Liliemark, J

Published
2003

22. Intensive chemotherapy in patients with chronic myelogenous leukaemia(CML) in accelerated or blastic phase--a report from the Swedish CMLGroup.

Author

Axdorph, U, Stenke, L, Grimfors, G, Carneskog, J, Hansen, J, Linder, O, Ljungman, P, Lofvenberg, E, Malm, C, Simonsson, B, Turesson, I, Vilen, L, Uden, AM, Bjorkholm, M, Axdorph, U, Stenke, L, Grimfors, G, Carneskog, J, Hansen, J, Linder, O, Ljungman, P, Lofvenberg, E, Malm, C, Simonsson, B, Turesson, I, Vilen, L, Uden, AM, and Bjorkholm, M

Published
2002

23. Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemiatreated with intensive chemotherapy.

Author

Oberg, G, Killander, A, Bjoreman, M, Gahrton, G, Grimfors, G, Gruber, A, Hast, R, Lerner, R, Liliemark, J, Mattson, S, Paul, C, Simonsson, B, Stalfelt, AM, Stenke, L, Tidefelt, U, Uden, AM, Bjorkholm, M, Oberg, G, Killander, A, Bjoreman, M, Gahrton, G, Grimfors, G, Gruber, A, Hast, R, Lerner, R, Liliemark, J, Mattson, S, Paul, C, Simonsson, B, Stalfelt, AM, Stenke, L, Tidefelt, U, Uden, AM, and Bjorkholm, M

Published
2002

24. High-dose cytarabine in upfront therapy for adult patients with acutelymphoblastic leukaemia.

Author

Hallbook, H, Simonsson, B, Ahlgren, T, Bjorkholm, M, Carneskog, J, Grimfors, G, Hast, R, Karlsson, K, Kimby, E, Lerner, R, Linder, O, Linderholm, M, Lofvenberg, E, Malm, C, Nilsson, PG, Paul, C, Stenke, L, Stockelberg, D, Tidefelt, U, Turesson, I, Uden-Blome, AM, Vilen, L, Wahlin, A, Winquist, I, Smedmyr, B, Hallbook, H, Simonsson, B, Ahlgren, T, Bjorkholm, M, Carneskog, J, Grimfors, G, Hast, R, Karlsson, K, Kimby, E, Lerner, R, Linder, O, Linderholm, M, Lofvenberg, E, Malm, C, Nilsson, PG, Paul, C, Stenke, L, Stockelberg, D, Tidefelt, U, Turesson, I, Uden-Blome, AM, Vilen, L, Wahlin, A, Winquist, I, and Smedmyr, B

Published
2002

25. Intensive chemotherapy in patients with chronic myelogenous leukaemia(CML) in accelerated or blastic phase--a report from the Swedish CMLGroup.

Author

Axdorph, U, Stenke, L, Grimfors, G, Carneskog, J, Hansen, J, Linder, O, Ljungman, P, Lofvenberg, E, Malm, C, Simonsson, B, Turesson, I, Vilen, L, Uden, AM, Bjorkholm, M, Axdorph, U, Stenke, L, Grimfors, G, Carneskog, J, Hansen, J, Linder, O, Ljungman, P, Lofvenberg, E, Malm, C, Simonsson, B, Turesson, I, Vilen, L, Uden, AM, and Bjorkholm, M

Published
2002

28. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells

Author

Xu, DW, Wang, Q, Gruber, A, Bjorkholm, M, Chen, ZG, Zaid, A, Selivanova, G, Peterson, C, Wiman, KG, Pisa, P, Xu, DW, Wang, Q, Gruber, A, Bjorkholm, M, Chen, ZG, Zaid, A, Selivanova, G, Peterson, C, Wiman, KG, and Pisa, P

Abstract

The p53 tumor suppressor protein inhibits the formation of tumors through induction of cell cycle arrest and/or apoptosis, In the present study we demonstrated that p53 is also a powerful inhibitor of human telomerase reverse transcriptase (hTERT), a key component for telomerase, Activation of either exogenous temperature-sensitive (ts) p53 in BL41 Burkitt lymphoma cells or endogenous wild type (wt) p53 at a physiological level in MCF-7 breast carcinoma cells triggered a rapid downregulation of hTERT mRNA expression, independently of the induction of the p53 target gene p21, Co-transfection of an hTERT promoter construct with wt p53 but not mutant p53 in HeLa cells inhibited the hTERT promoter activity. Furthermore, the activation of the hTERT promoter in Drosophila Schneider SL2 cells was completely dependent on the ectopic expression of Sp1 and was abrogated by wt p53, Finally, wt p53 inhibited Sp1 binding to the hTERT proximal promoter by forming a p53-Sp1 complex. Since activation of telomerase, widely observed in human tumor cell lines and primary tumors, is a critical step in tumorigenesis, wt p53-triggered inhibition of hTERT/telomerase expression may reflect yet another mechanism of p53-mediated tumor suppression. Our findings provide new insights into both the biological function of p53 and the regulation of hTERT/telomerase expression.

Published
2000

29. Intensive treatment in order to minimize the ph-positive clone in CML

Author

Simonsson, B, Oberg, G, Bjoreman, M, Bjorkholm, M, Carneskog, J, Gahrton, G, Hast, R, Lang-Nielsen, J, Lofvenberg, E, Malm, C, Turesson, I, Uden, A-M, Vilen, L, Weis-Bjerrum, O, Simonsson, B, Oberg, G, Bjoreman, M, Bjorkholm, M, Carneskog, J, Gahrton, G, Hast, R, Lang-Nielsen, J, Lofvenberg, E, Malm, C, Turesson, I, Uden, A-M, Vilen, L, and Weis-Bjerrum, O

Published
1996

30. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support

Author

Johnsen, H E, Bjorkstrand, B, Carlson, K, Gruber, A, Blystad, A, Fast, A, Boesen, A M, Bjorkholm, M, Sallerfors, B, Ruutu, T, Carneskog, J, Malm, A, Geisler, C, Lehtinen, M, Schroder, H, Brinch, L, Remes, K, Tidefelt, U, Heilman, C, Hornsten, P, Thorling, K, Daugaard, G, Johnsen, H E, Bjorkstrand, B, Carlson, K, Gruber, A, Blystad, A, Fast, A, Boesen, A M, Bjorkholm, M, Sallerfors, B, Ruutu, T, Carneskog, J, Malm, A, Geisler, C, Lehtinen, M, Schroder, H, Brinch, L, Remes, K, Tidefelt, U, Heilman, C, Hornsten, P, Thorling, K, and Daugaard, G

Published
1996

35. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies from EBV-positive Hodgkin's disease.

Author

Frisan, T, Sjoberg, J, Dolcetti, R, Boiocchi, M, De Re, V, Carbone, A, Brautbar, C, Battat, S, Biberfeld, P, Eckman, M, Ost, Å, Christensson, B, Sundstrom, C, Bjorkholm, M, Pisa, P, Masucci, MG, Frisan, T, Sjoberg, J, Dolcetti, R, Boiocchi, M, De Re, V, Carbone, A, Brautbar, C, Battat, S, Biberfeld, P, Eckman, M, Ost, Å, Christensson, B, Sundstrom, C, Bjorkholm, M, Pisa, P, and Masucci, MG

Published
1995

36. Mitoxantrone, etopside and ara-C vs doxorubicin-DNA, ara-C, thioguanine, voncristine and prednisolone in the treatment of patients with acute myelocytic leukemia. A randomized comparison.

Author

Bjorkholm, M, Liliemark, J, Gahrton, G, Grimfors, G, Gruber, A, Hast, R, Juliusson, G, Jarnmark, M, Killander, A, Kimby, E, Lerner, R, Ljungman, P, Lonnqvist, B, Palmblad, J, Paul, C, Pettersson, C, Simonsson, B, Stalfelt, A-M, Stenke, L, Sundstrom, C, Tidefelt, U, Uden, A-M, Oberg, G, Ost, Å, Bjorkholm, M, Liliemark, J, Gahrton, G, Grimfors, G, Gruber, A, Hast, R, Juliusson, G, Jarnmark, M, Killander, A, Kimby, E, Lerner, R, Ljungman, P, Lonnqvist, B, Palmblad, J, Paul, C, Pettersson, C, Simonsson, B, Stalfelt, A-M, Stenke, L, Sundstrom, C, Tidefelt, U, Uden, A-M, Oberg, G, and Ost, Å

Published
1995

37. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies from EBV-positive Hodgkin's disease.

Author

Frisan, T, Sjoberg, J, Dolcetti, R, Boiocchi, M, De Re, V, Carbone, A, Brautbar, C, Battat, S, Biberfeld, P, Eckman, M, Ost, Å, Christensson, B, Sundstrom, C, Bjorkholm, M, Pisa, P, Masucci, MG, Frisan, T, Sjoberg, J, Dolcetti, R, Boiocchi, M, De Re, V, Carbone, A, Brautbar, C, Battat, S, Biberfeld, P, Eckman, M, Ost, Å, Christensson, B, Sundstrom, C, Bjorkholm, M, Pisa, P, and Masucci, MG

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results